Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed metastatic adenocarcinoma of the pancreas
• •* Progressed after first-line or adjuvant gemcitabine-based chemotherapy
• •Measurable disease as assessed by RECIST criteria
• •No known brain metastasis or symptomatic carcinomatous leptomeningitis
• •PATIENT CHARACTERISTICS:
• •WHO performance status 0-1
• •Life expectancy ≥ 3 months
• •ANC ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hemoglobin ≥ 9 g/dL
• •Creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Total bilirubin ≤ 2.5 times ULN
• •ALT/AST ≤ 5 times ULN
• •LVEF ≥ 55%
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No significant comorbidities, including any of the following:
• •* Cardiovascular disease
• •* Documented history of congestive heart failure
• •* Uncontrolled, high-risk arrhythmia
• •* Angina pectoris requiring treatment
• •* Clinically significant valvular disease
• •* Evidence of transmural myocardial infarction by ECG
• •* Uncontrolled hypertension
• •* Active bleeding
• •* Clinically significant active infection
• •* Severe dyspnea at rest
• •* Oxygen-dependency
• •No other malignancy except basal cell carcinoma of the skin
• •No severe hypersensitivity to cetuximab or trastuzumab
• •No medical or psychological condition that would preclude study completion or giving informed consent
• •No legal incapacity or limited legal capacity
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •No prior cetuximab or trastuzumab
• •No other concurrent experimental drugs or anticancer therapy